Morgan Stanley Initiates Coverage On Adarx Pharmaceuticals with Overweight Rating, Announces Price Target of $32
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsInitiationPrice Target
Morgan Stanley analyst Michael Ulz initiates coverage on Adarx Pharmaceuticals (NASDAQ:ADRX) with a Overweight rating and announces Price Target of $32.
Morgan Stanley analyst Michael Ulz initiates coverage on Adarx Pharmaceuticals (NASDAQ:ADRX) with a Overweight rating and announces Price Target of $32.